Scilex Holding (SCLX) EPS (Basic) Growth (1y) (2021 - 2026)
Scilex Holding (SCLX) EPS (Basic) Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | -0.10% |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 284.05% |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -130.68% |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | -92.05% |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 2.26% |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 65.24% |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -636.10% |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -108.11% |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -69.49% |
| 10 | Scilex Holding | 39.35 Mn | -73.44 Mn | 3.97 Mn | -124.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.95% |
| Dec 31, 2025 | -173,941.23% |
| Sep 30, 2025 | -1,732.32% |
| Jun 30, 2025 | -63,792.60% |
| Mar 31, 2025 | 99.94% |
| Dec 31, 2024 | 70.01% |
| Sep 30, 2024 | -5,380.51% |
| Jun 30, 2024 | -77.63% |
| Mar 31, 2024 | -109,541.74% |
| Dec 31, 2023 | 99.88% |
| Sep 30, 2023 | -138.65% |
| Jun 30, 2023 | 81.98% |
| Mar 31, 2023 | 59.04% |
| Dec 31, 2022 | -4,679.28% |
| Sep 30, 2022 | 10,097.51% |
| Jun 30, 2022 | -8,552.92% |
| Mar 31, 2022 | -3,636.89% |
| Dec 31, 2021 | -558.35% |
| Sep 30, 2021 | -736.16% |